Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

# Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade. **Read the full article:** [CNBC](https://www.cnbc.com/2026/06/16/biotech-deals-ipo-pharma-dealmaking-2026.html) *This article was originally published by CNBC. MoneyWiseInc provides expert curation of the best financial content from trusted sources.*